Genovis publish a new share issue prospectus


Finansinspektionen (the Swedish Financial Supervisory Authority) approved on April 4 Genovis prospectus for a new share issue with preference for existing shareholders, the subscription period is April 13 – May 6 2011. Starting Tuesday the 5 of April the prospectus will be available in Swedish on Genovis and Finansinspektionens home page.

Genovis AB (publ)

The board of directors

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 46 10 12 35

Genovis develops and designs smart nanoparticles for preclinical imaging and diagnostics and also develops and sells tools for modification of antibodies.Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission ( 46 (0)31 745 50 00) is the Company’s certified adviser.

About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North


Documents & Links